---
document_datetime: 2025-12-21 09:02:15
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/saphnelo.html
document_name: saphnelo.html
version: success
processing_time: 0.1124
conversion_datetime: 2025-12-25 09:16:43.873573
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Saphnelo

[RSS](/en/individual-human-medicine.xml/67533)

##### Authorised

This medicine is authorised for use in the European Union

anifrolumab Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Saphnelo](#news-on)
- [More information on Saphnelo](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Saphnelo is a medicine used as an add-on treatment in adults with systemic lupus erythematosus (SLE), a disease in which the immune system (the body's natural defences) attacks normal cells and tissues, causing inflammation and organ damage.

Saphnelo is given to patients who have antibodies against their own cells (autoantibodies) and whose disease is still moderate to severe despite standard treatment.

Saphnelo contains the active substance anifrolumab.

Expand section

Collapse section

## How is Saphnelo used?

Saphnelo can only be obtained with a prescription and treatment should be started and supervised by a doctor who has experience in the treatment of SLE.

Saphnelo is given as an infusion (drip) into a vein. The recommended dose is 300 mg given over 30 minutes every four weeks. The doctor may interrupt or stop treatment if the patient develops reactions linked to the infusion. Patients who have previously had such reactions may be given preventive medicines before treatment.

For more information about using Saphnelo, see the package leaflet or contact your doctor or pharmacist.

## How does Saphnelo work?

In SLE, a protein called type I interferon (IFN) is involved in causing the immune system to attack normal cells and tissues. Type I IFN acts by attaching to a protein called type I IFN receptor.

The active substance in Saphnelo, anifrolumab, is a monoclonal antibody (another type of protein) designed to attach to this receptor, thereby preventing type I IFN from binding to it. This blocks the action of type I IFN and reduces the inflammation and organ damage that occur in SLE.

## What benefits of Saphnelo have been shown in studies?

Two main studies found that 300 mg of Saphnelo was more effective as an add-on to standard treatment than placebo (a dummy treatment) in reducing SLE disease activity, measured using a standard index known as BICLA. The studies involved a total of 822 adults with moderate to severe autoantibody-positive SLE who were treated with Saphnelo for one year.

In the first study, disease activity decreased in 47% of patients treated with Saphnelo compared with 30% of patients who were given placebo. In the second study, disease activity decreased in 48% of patients treated with Saphnelo compared with 32% of those who received placebo.

## What are the risks associated with Saphnelo?

The most common side effects with Saphnelo (which may affect more than 1 in 10 people) are upper respiratory tract (nose and throat) infection and bronchitis (inflammation of the airways in the lungs).

The most common serious side effect (which may affect up to 1 in 100 people) is herpes zoster (shingles).

For the full list of side effects and restrictions of Saphnelo, see the package leaflet.

## Why is Saphnelo authorised in the EU?

The European Medicines Agency considered that Saphnelo used as an add-on treatment provides a modest, but clinically meaningful reduction in disease activity in patients with SLE, for whom there is a high unmet need for new therapies. As the safety of the medicine is considered acceptable, the Agency concluded that Saphnelo's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Saphnelo?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Saphnelo have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Saphnelo are continuously monitored. Suspected side effects reported with the medicine are carefully evaluated and any necessary action taken to protect patients.

## Other information about Saphnelo

Saphnelo received a marketing authorisation valid throughout the EU on 14 February 2022.

Saphnelo : EPAR - Medicine Overview

Reference Number: EMA/6640/2022

English (EN) (116.95 KB - PDF)

**First published:** 21/02/2022

[View](/en/documents/overview/saphnelo-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-869)

български (BG) (121.29 KB - PDF)

**First published:**

21/02/2022

[View](/bg/documents/overview/saphnelo-epar-medicine-overview_bg.pdf)

español (ES) (99.4 KB - PDF)

**First published:**

21/02/2022

[View](/es/documents/overview/saphnelo-epar-medicine-overview_es.pdf)

čeština (CS) (117.93 KB - PDF)

**First published:**

21/02/2022

[View](/cs/documents/overview/saphnelo-epar-medicine-overview_cs.pdf)

dansk (DA) (99.13 KB - PDF)

**First published:**

21/02/2022

[View](/da/documents/overview/saphnelo-epar-medicine-overview_da.pdf)

Deutsch (DE) (99.6 KB - PDF)

**First published:**

21/02/2022

[View](/de/documents/overview/saphnelo-epar-medicine-overview_de.pdf)

eesti keel (ET) (98.74 KB - PDF)

**First published:**

21/02/2022

[View](/et/documents/overview/saphnelo-epar-medicine-overview_et.pdf)

ελληνικά (EL) (129.1 KB - PDF)

**First published:**

21/02/2022

[View](/el/documents/overview/saphnelo-epar-medicine-overview_el.pdf)

français (FR) (99.78 KB - PDF)

**First published:**

21/02/2022

[View](/fr/documents/overview/saphnelo-epar-medicine-overview_fr.pdf)

hrvatski (HR) (113.22 KB - PDF)

**First published:**

21/02/2022

[View](/hr/documents/overview/saphnelo-epar-medicine-overview_hr.pdf)

italiano (IT) (99.19 KB - PDF)

**First published:**

21/02/2022

[View](/it/documents/overview/saphnelo-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (118.78 KB - PDF)

**First published:**

21/02/2022

[View](/lv/documents/overview/saphnelo-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (117.64 KB - PDF)

**First published:**

21/02/2022

[View](/lt/documents/overview/saphnelo-epar-medicine-overview_lt.pdf)

magyar (HU) (112.65 KB - PDF)

**First published:**

21/02/2022

[View](/hu/documents/overview/saphnelo-epar-medicine-overview_hu.pdf)

Malti (MT) (118.48 KB - PDF)

**First published:**

21/02/2022

[View](/mt/documents/overview/saphnelo-epar-medicine-overview_mt.pdf)

Nederlands (NL) (99.58 KB - PDF)

**First published:**

21/02/2022

[View](/nl/documents/overview/saphnelo-epar-medicine-overview_nl.pdf)

polski (PL) (117.93 KB - PDF)

**First published:**

21/02/2022

[View](/pl/documents/overview/saphnelo-epar-medicine-overview_pl.pdf)

português (PT) (99.33 KB - PDF)

**First published:**

21/02/2022

[View](/pt/documents/overview/saphnelo-epar-medicine-overview_pt.pdf)

română (RO) (115.37 KB - PDF)

**First published:**

21/02/2022

[View](/ro/documents/overview/saphnelo-epar-medicine-overview_ro.pdf)

slovenčina (SK) (116.7 KB - PDF)

**First published:**

21/02/2022

[View](/sk/documents/overview/saphnelo-epar-medicine-overview_sk.pdf)

slovenščina (SL) (111.37 KB - PDF)

**First published:**

21/02/2022

[View](/sl/documents/overview/saphnelo-epar-medicine-overview_sl.pdf)

Suomi (FI) (98.84 KB - PDF)

**First published:**

21/02/2022

[View](/fi/documents/overview/saphnelo-epar-medicine-overview_fi.pdf)

svenska (SV) (98.85 KB - PDF)

**First published:**

21/02/2022

[View](/sv/documents/overview/saphnelo-epar-medicine-overview_sv.pdf)

Saphnelo : EPAR - Risk management plan

English (EN) (506.05 KB - PDF)

**First published:** 21/02/2022

**Last updated:** 18/12/2025

[View](/en/documents/rmp/saphnelo-epar-risk-management-plan_en.pdf)

## Product information

Saphnelo : EPAR - Product Information

English (EN) (929.32 KB - PDF)

**First published:** 21/02/2022

**Last updated:** 18/12/2025

[View](/en/documents/product-information/saphnelo-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-734)

български (BG) (1.04 MB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/bg/documents/product-information/saphnelo-epar-product-information_bg.pdf)

español (ES) (868.79 KB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/es/documents/product-information/saphnelo-epar-product-information_es.pdf)

čeština (CS) (3.47 MB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/cs/documents/product-information/saphnelo-epar-product-information_cs.pdf)

dansk (DA) (881.05 KB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/da/documents/product-information/saphnelo-epar-product-information_da.pdf)

Deutsch (DE) (1.02 MB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/de/documents/product-information/saphnelo-epar-product-information_de.pdf)

eesti keel (ET) (982.33 KB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/et/documents/product-information/saphnelo-epar-product-information_et.pdf)

ελληνικά (EL) (1.03 MB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/el/documents/product-information/saphnelo-epar-product-information_el.pdf)

français (FR) (1.03 MB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/fr/documents/product-information/saphnelo-epar-product-information_fr.pdf)

hrvatski (HR) (994.86 KB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/hr/documents/product-information/saphnelo-epar-product-information_hr.pdf)

íslenska (IS) (928.32 KB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/is/documents/product-information/saphnelo-epar-product-information_is.pdf)

italiano (IT) (1005.52 KB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/it/documents/product-information/saphnelo-epar-product-information_it.pdf)

latviešu valoda (LV) (989.09 KB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/lv/documents/product-information/saphnelo-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1012.83 KB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/lt/documents/product-information/saphnelo-epar-product-information_lt.pdf)

magyar (HU) (1.04 MB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/hu/documents/product-information/saphnelo-epar-product-information_hu.pdf)

Malti (MT) (1.02 MB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/mt/documents/product-information/saphnelo-epar-product-information_mt.pdf)

Nederlands (NL) (928.54 KB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/nl/documents/product-information/saphnelo-epar-product-information_nl.pdf)

norsk (NO) (869.32 KB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/no/documents/product-information/saphnelo-epar-product-information_no.pdf)

polski (PL) (1.05 MB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/pl/documents/product-information/saphnelo-epar-product-information_pl.pdf)

português (PT) (950.7 KB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/pt/documents/product-information/saphnelo-epar-product-information_pt.pdf)

română (RO) (995.76 KB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/ro/documents/product-information/saphnelo-epar-product-information_ro.pdf)

slovenčina (SK) (1.01 MB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/sk/documents/product-information/saphnelo-epar-product-information_sk.pdf)

slovenščina (SL) (2.15 MB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/sl/documents/product-information/saphnelo-epar-product-information_sl.pdf)

Suomi (FI) (918.33 KB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/fi/documents/product-information/saphnelo-epar-product-information_fi.pdf)

svenska (SV) (966.84 KB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/sv/documents/product-information/saphnelo-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** X/0023 12/12/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Saphnelo : EPAR - All authorised presentations

English (EN) (40.99 KB - PDF)

**First published:** 21/02/2022

**Last updated:** 18/12/2025

[View](/en/documents/all-authorised-presentations/saphnelo-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-184)

български (BG) (47.61 KB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/bg/documents/all-authorised-presentations/saphnelo-epar-all-authorised-presentations_bg.pdf)

español (ES) (41.02 KB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/es/documents/all-authorised-presentations/saphnelo-epar-all-authorised-presentations_es.pdf)

čeština (CS) (47.28 KB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/cs/documents/all-authorised-presentations/saphnelo-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (43.41 KB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/da/documents/all-authorised-presentations/saphnelo-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (42.78 KB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/de/documents/all-authorised-presentations/saphnelo-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (38.16 KB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/et/documents/all-authorised-presentations/saphnelo-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (44.75 KB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/el/documents/all-authorised-presentations/saphnelo-epar-all-authorised-presentations_el.pdf)

français (FR) (41.68 KB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/fr/documents/all-authorised-presentations/saphnelo-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (43.08 KB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/hr/documents/all-authorised-presentations/saphnelo-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (43.26 KB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/is/documents/all-authorised-presentations/saphnelo-epar-all-authorised-presentations_is.pdf)

italiano (IT) (39.66 KB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/it/documents/all-authorised-presentations/saphnelo-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (45.61 KB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/lv/documents/all-authorised-presentations/saphnelo-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (45.69 KB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/lt/documents/all-authorised-presentations/saphnelo-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (44.56 KB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/hu/documents/all-authorised-presentations/saphnelo-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (44.9 KB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/mt/documents/all-authorised-presentations/saphnelo-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (39.55 KB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/nl/documents/all-authorised-presentations/saphnelo-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (42.14 KB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/no/documents/all-authorised-presentations/saphnelo-epar-all-authorised-presentations_no.pdf)

polski (PL) (46.01 KB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/pl/documents/all-authorised-presentations/saphnelo-epar-all-authorised-presentations_pl.pdf)

português (PT) (42.41 KB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/pt/documents/all-authorised-presentations/saphnelo-epar-all-authorised-presentations_pt.pdf)

română (RO) (43.6 KB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/ro/documents/all-authorised-presentations/saphnelo-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (45.63 KB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/sk/documents/all-authorised-presentations/saphnelo-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (40.51 KB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/sl/documents/all-authorised-presentations/saphnelo-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (38.21 KB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/fi/documents/all-authorised-presentations/saphnelo-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (40.29 KB - PDF)

**First published:**

21/02/2022

**Last updated:**

18/12/2025

[View](/sv/documents/all-authorised-presentations/saphnelo-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Saphnelo Active substance anifrolumab International non-proprietary name (INN) or common name anifrolumab Therapeutic area (MeSH) Lupus Erythematosus, Systemic Anatomical therapeutic chemical (ATC) code L04AG11

### Pharmacotherapeutic group

Monoclonal antibodies

### Therapeutic indication

Saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE), despite standard therapy.

## Authorisation details

EMA product number EMEA/H/C/004975

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

AstraZeneca AB

SE-151 85 Sodertalje

Opinion adopted 16/12/2021 Marketing authorisation issued 14/02/2022 Revision 8

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Saphnelo : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (146.13 KB - PDF)

**First published:** 18/10/2022

**Last updated:** 18/12/2025

[View](/en/documents/procedural-steps-after/saphnelo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Saphnelo-H-C-004975-X-0023 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/348230/2025

English (EN) (3.43 MB - PDF)

**First published:** 18/12/2025

[View](/en/documents/variation-report/saphnelo-h-c-004975-x-0023-epar-assessment-report-variation_en.pdf)

Saphnelo-H-C-PSUSA-00010980-202307 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/245971/2024

English (EN) (91.34 KB - PDF)

**First published:** 24/05/2024

[View](/en/documents/scientific-conclusion/saphnelo-h-c-psusa-00010980-202307-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Saphnelo : EPAR - Public assessment report

Adopted

Reference Number: EMA/4079/2022

English (EN) (11.39 MB - PDF)

**First published:** 21/02/2022

[View](/en/documents/assessment-report/saphnelo-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Saphnelo

Adopted

Reference Number: EMA/CHMP/683625/2021

English (EN) (125.71 KB - PDF)

**First published:** 17/12/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-saphnelo_en.pdf)

#### News on Saphnelo

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-december-2021) 17/12/2021

#### More information on Saphnelo

- [EMEA-001435-PIP02-16-M02 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001435-pip02-16-m02)

**This page was last updated on** 18/12/2025

## Share this page

[Back to top](#main-content)